

Ziprasidone

Catalog No: tcsc1071



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

146939-27-7

Formula:

$C_{21}H_{21}ClN_4OS$

Pathway:

GPCR/G Protein;Neuronal Signaling;Neuronal Signaling;GPCR/G Protein

Target:

Dopamine Receptor;Dopamine Receptor;5-HT Receptor;5-HT Receptor

Purity / Grade:

>98%

Solubility:

DMSO : 13.5 mg/mL (32.69 mM; Need ultrasonic)

Alternative Names:

CP-88059

Observed Molecular Weight:

412.94

Product Description

Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.


IC50 value:

Target: 5-HT receptor; Dopamine receptor

Ziprasidone possesses an in vitro 5-HT_{2A}/dopamine D₂ receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT_{2A} receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D₂ receptor antagonism. Ziprasidone also has high affinity for the 5-HT_{1A}, 5-HT_{1D} and 5-HT_{2C} receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT₂ and D₂ receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].

Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; Schizophrenia

FDA Approved Date: February 2001



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!